Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Mirum Pharmaceuticals to Participate at Four Upcoming Conferences

MIRM

FOSTER CITY, Calif.

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM), a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases, today announced that company management will participate at the following conferences in February and March.

  • SVB Leerink 9th Annual Global Healthcare Conference
    • Location: New York, NY
    • Presentation date: Wednesday February 26, 2020
    • Presentation time: 9:30 a.m. ET
  • Cowen 40th Annual Healthcare Conference
    • Location: Boston, MA
    • Presentation date: Monday March 2, 2020
    • Presentation time: 2:10 p.m. ET
  • Raymond James 41st Annual Institutional Investors Conference
    • Location: Orlando, FL
    • Presentation date: Wednesday March 4, 2020
    • Presentation time: 9:15 a.m. ET

A live audio webcast and archive of the presentations outline above will be available at http://ir.mirumpharma.com

Additionally, the company will be participating the 32nd Annual ROTH Conference, and will be on a panel on Monday March 16 at 11:00 a.m. discussing Orphan Therapeutics.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company’s lead product candidate, maralixibat, is an investigational oral drug in development for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC). For more information, visit MirumPharma.com. Follow Mirum on Twitter, Facebook and LinkedIn.

Media Contact:
Heidi Chokeir, Ph.D.
Canale Communications
619-203-5391
heidi@canalecomm.com

Investor Contact:
Ian Clements, Ph.D.
650-667-4085
ir@mirumpharma.com



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today